Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Gritstone bio, Inc. | d618135d10q.htm |
| EX-31.2 - EX-31.2 - Gritstone bio, Inc. | d618135dex312.htm |
| EX-31.1 - EX-31.1 - Gritstone bio, Inc. | d618135dex311.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Gritstone Oncology, Inc. (the “Company”) for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Andrew Allen, M.D., Ph.D., President and Chief Executive Officer of the Company, and Jean-Marc Bellemin, Chief Financial Officer of the Company, respectively, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: November 14, 2018 | /s/ Andrew Allen | |||||
| Andrew Allen, M.D., Ph.D. | ||||||
| President and Chief Executive Officer (Principal Executive Officer) | ||||||
| Date: November 14, 2018 | /s/ Jean-Marc Bellemin | |||||
| Jean-Marc Bellemin | ||||||
| Chief Financial Officer (Principal Financial Officer) | ||||||